Feeney E R, Mallon P W. HIV and HAART-associated dyslipidemia[J]. Open Cardiovasc Med J, 2011,5(1):49.
[8]
Pefura Yone E W, Betyoumin A F, Kengne A P, et al. First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: across-sectional study[J]. AIDS Res Ther,2011,8: 33.
Domingo P, Cabeza M C, Pruvost A, et al. Relationship between HIV/Highly active antiretroviral therapy( HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens [J]. Clin Infect Dis, 2010, 50(7): 1033.
Croxtall J D, Perry C M. Lopinavir ritonavir: a review of its use in the management of HIV-1 infection [J]. Drugs,2010,70 (14): 1885.
[30]
Nery M W, Martelli C M, Turchi M D.Dyslipidemia in AIDS patients on highly active antiretroviral therapy [J]. Braz J Infect Dis, 2011,15(2):151.
[31]
Jones R, Sawleshwarkar S, Michailidis C, et al. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone[J]. HIV Med, 2005, 6(6):396.